Peer-Reviewed Paper Featuring Titan Medical’s Single-Port Robotic Surgical Platform in General Surgery Published in Surgical Endoscopy

TORONTO–(BUSINESS WIRE)–Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or the
, a medical device company focused on the design and
development of a single-port robotic surgical system for application in
minimally invasive surgery (“MIS”), announces that a peer-reviewed
multi-faculty paper featuring Titan’s single-port platform has been
published in the January 2019 issue of Surgical Endoscopy. The
paper highlights the feasibility, safety and ease of use of Titan’s
single-port robotic technology for general surgery procedures and is
available here.

This European experience paper was authored by Barbara Seeliger, M.D.,
Michele Diana, M.D., Jacques Marescaux, M.D., FACS, FRCS and Lee
Swanstrom, M.D., FACS, from IHU-Strasbourg Institute of Image-Guided
Surgery in France; Jelle Ruurda, M.D., Ph.D. from University Medical
Center in Utrecht, the Netherlands; and Konstantinos Konstantinidis,
M.D., Ph.D., FACS from Athens Medical Center in Greece.

“We’re delighted this multi-faculty paper of extensive preclinical work
conducted under the guidance of internationally renowned general
surgeons has been published in a well-respected, peer-reviewed surgical
endoscopy journal,” said David McNally, president and chief executive
officer of Titan Medical. “It is exciting and validating to see the
feasibility, safety and ease of use of our single-port technology
demonstrated in the hands of these KOL surgeons. The feedback from this
experience was instrumental in driving the system enhancements of our
next-generation platform, which we announced last week. We look forward
to providing this newest system to our surgeon champions in the coming
months as we progress toward U.S. and EU regulatory filings later this

Dr. Swanstrom said, “The feasibility studies conducted at IHU Strasbourg
with Titan’s single-port platform demonstrated that the technology can
be safely used in a wide variety of general surgery procedures.
Additionally, I believe the 3D HD visualization, ergonomic interface and
controls dramatically minimized the learning curve for this new
technology. The IHU-Strasbourg team is pleased to be able to evaluate
this enabling technology and we look forward to using it to expand the
frontiers of single-port surgery.”

“I am happy to be part of this multi-faculty feasibility study
evaluating Titan’s enabling single-port robotic platform,” commented Dr.
Ruurda. “Single-port robotic surgery with the right tools and
capabilities like Titan’s supports the natural evolution of minimally
invasive surgery to fewer incisions. The study showed that a variety of
general surgery procedures were completed safely, and my experience
demonstrated the technology offers versatility in multi-quadrant upper
GI and lower GI procedures.”

Dr. Konstantinidis added, “It took me very little time to adjust to
Titan’s single-port platform during the evaluation of the technology.
The 3D HD visualization, natural handle interface, dextrous
end-effectors and highly ergonomic posture should greatly facilitate the
adoption of this platform. I am very excited about the enhancements
incorporated into the next-generation platform based on the feedback
from our study, as there is no doubt in my mind that single-port robotic
surgery is the next frontier.”

About Titan Medical Inc.

Titan Medical Inc. is focused on computer-assisted robotic surgical
technologies for application in minimally invasive surgery. The Company
is developing the SPORT Surgical System, a single-port robotic surgical
system comprised of a surgeon-controlled patient cart that includes a 3D
high-definition vision system and multi-articulating instruments for
performing MIS procedures, and a surgeon workstation that provides an
advanced ergonomic interface to the patient cart and a 3D endoscopic
view inside the patient’s body. Titan intends to initially pursue
focused surgical indications for the SPORT Surgical System, which may
include one or more of gynecologic, urologic, colorectal or general
abdominal procedures.

For more information, please visit the Company’s website at

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect
the current expectations of management of the Company’s future growth,
results of operations, performance and business prospects and
opportunities. Wherever possible, words such as “may”, “would”, “could”,
“will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”,
“potential for” and similar expressions have been used to identify these
forward-looking statements. These statements reflect management’s
current beliefs with respect to future events and are based on
information currently available to management. Forward-looking
statements involve significant risks, uncertainties and assumptions.
Many factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by such
forward-looking statements, including, without limitation, those listed
in the “Risk Factors” section of the Company’s Annual Information Form
dated March 31, 2018 (which may be viewed at
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking statements prove
incorrect, actual results, performance or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. These factors should be
considered carefully, and prospective investors should not place undue
reliance on the forward-looking statements. Although the forward-looking
statements contained in the news release are based upon what management
currently believes to be reasonable assumptions, the Company cannot
assure prospective investors that actual results, performance or
achievements will be consistent with these forward-looking statements.